Characteristics, treatment patterns, and prognostic factors in small cell lung cancer transformation of advanced non-small cell lung cancer with epidermal growth factor receptor mutation after tyrosine kinase inhibitor therapy

被引：0
|
作者：
Liao, Ying-Ting
Chiang, Chi-Lu
Sun, Ruei-Lin
Yeh, Yi-chen
Huang, Hsu-Ching
Shen, Chia-I
Tseng, Yen-Han
Luo, Yung-Hung
Chen, Yuh-Min
Whang-Peng, Jacqueline
机构：
[1] Taipei Vet Gen Hosp, Taipei, Taiwan
[2] Taipei Vet Gen Hosp, Dept Pathol, Taipei, Taiwan
[3] Taipei Med Univ, Taipei, Taiwan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20569
引用
收藏
页数：1
相关论文
共 50 条
  • [31] KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
    Massarelli, Erminia
    Varella-Garcia, Marileila
    Tang, Ximing
    Xavier, Ana C.
    Ozburn, Natalie C.
    Liu, Diane D.
    Bekele, Benjamin N.
    Herbst, Roy S.
    Wistuba, Ignacio I.
    CLINICAL CANCER RESEARCH, 2007, 13 (10) : 2890 - 2896
  • [32] Mutation in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer (NSCLC)
    Tsai, C
    Chiu, C
    Chou, T
    Li, L
    Chang, K
    Chen, Y
    Tsai, S
    Perng, R
    LUNG CANCER, 2005, 49 : S113 - S113
  • [33] Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer
    Zaarour, Mazen
    Weerasinghe, Chanudi
    Nazha, Bassel
    Hassan, Samer
    Atallah, Jean-Paul
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (11) : 1327 - 1336
  • [34] Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors
    Nurwidya, Fariz
    Takahashi, Fumiyuki
    Murakami, Akiko
    Kobayashi, Isao
    Kato, Motoyasu
    Shukuya, Takehito
    Tajima, Ken
    Shimada, Naoko
    Takahashi, Kazuhisa
    RESPIRATORY INVESTIGATION, 2014, 52 (02) : 82 - 91
  • [35] Vascular endothelial growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small cell lung cancer
    Spagnuolo, A.
    Palazzolo, G.
    Sementa, C.
    Gridelli, C.
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (04) : 491 - 506
  • [36] Is there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wildtype non-small cell lung cancer?
    Arriola, Edurne
    Taus, Alvaro
    Casadevall, David
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2015, 6 (04): : 45 - 56
  • [37] Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
    Kanazu, M.
    Mori, M.
    Shiroyama, T.
    Nagatomo, I.
    Ihara, S.
    Komuta, K.
    Suzuki, H.
    Hirashima, T.
    Kimura, M.
    Imamura, F.
    ANNALS OF ONCOLOGY, 2019, 30
  • [38] EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS IN TREATMENT OF NON-SMALL CELL LUNG CANCER
    Kilickap, Saadettin
    NOBEL MEDICUS, 2018, 14 (03): : 5 - 8
  • [39] The Role of Mutation Status of the Epidermal Growth Factor Receptor Gene In Advanced Non-Small Cell Lung Cancer
    Vaguliene, Neringa
    Zemaitis, Marius
    Sarauskas, Valdas
    Vitkauskiene, Astra
    Miliauskas, Skaidrius
    MEDICINA-LITHUANIA, 2012, 48 (04): : 175 - 181
  • [40] Small Molecule Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Non Small Cell Lung Cancer Treatment
    Schettino, Clorinda
    Bareschino, Maria Anna
    Maione, Paolo
    Rossi, Antonio
    Ciardiello, Fortunato
    Gridelli, Cesare
    CURRENT CANCER THERAPY REVIEWS, 2007, 3 (04) : 226 - 235
12345